CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
31 10월 2023 - 8:05PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical
company focused on creating transformative gene-based medicines for
serious diseases, today announced that NASDAQ has halted trading of
the Company’s common stock.
The U.S. Food and Drug Administration’s (FDA)
Cellular, Tissue, and Gene Therapies Advisory Committee is meeting
today to review the Biologics License Application (BLA) for
exagamglogene autotemcel (exa-cel) for the treatment of sickle cell
disease (SCD) in people ages 12 and older with recurrent
vaso-occlusive crises.
The Advisory Committee meeting is scheduled for
9:00 AM ET. The briefing materials can be found on the FDA website
HERE.
The Prescription Drug User Fee Act date for
completion of the review of the BLA for exa-cel for SCD is December
8, 2023.
About CRISPR
TherapeuticsCRISPR Therapeutics is a leading gene
editing company focused on developing transformative gene-based
medicines for serious diseases using its proprietary CRISPR/Cas9
platform. CRISPR/Cas9 is a revolutionary gene editing technology
that allows for precise, directed changes to genomic
DNA. CRISPR Therapeutics has established a portfolio of
therapeutic programs across a broad range of disease areas
including hemoglobinopathies, oncology, regenerative medicine and
cardiometabolic diseases. To accelerate and expand its
efforts, CRISPR Therapeutics has established strategic
partnerships with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR
Therapeutics AG is headquartered in Zug, Switzerland,
with its wholly-owned U.S. subsidiary, CRISPR
Therapeutics, Inc., and R&D operations based in Boston,
Massachusetts and San Francisco, California, and business
offices in London, United Kingdom. For more information,
please visit www.crisprtx.com.
CRISPR THERAPEUTICS® standard character mark and
design logo are trademarks and registered trademarks of CRISPR
Therapeutics AG. All other trademarks and registered trademarks are
the property of their respective owners.
Investor Contact:Susan
Kim+1-617-307-7503susan.kim@crisprtx.com
Media Contact:Rachel
Eides+1-617-315-4493rachel.eides@crisprtx.com
CRISPR Therapeutics (NASDAQ:CRSP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
CRISPR Therapeutics (NASDAQ:CRSP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024